Vyome Holdings, Inc
HINDVyome Holdings, Inc in brief
Vyome Holdings, Inc is a listed company in the Biotechnology industry, based in San Clemente, California, USA. Its market value was $14 M on 7 October 2026, which makes it the 25,174th largest listed company in the world and the 4,223rd largest in the USA on this site. It employs about 18 people. Its largest product and service lines by sales in 2025 were Licensing and milestone fees – Luliconazole (37%) and Royalty income related to above product sales (9%). Its shares trade under the symbol HIND (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Vyome Holdings, Inc
On August 15, 2025, ReShape Lifesciences Inc. (now known as Vyome Holdings, Inc.) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended, by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company, and Vyome Therapeutics, Inc.. Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company. As a result of the Merger, the Company was renamed “Vyome Holdings, Inc.” and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.
From the company's annual report filed with the US SEC: read the report
Vyome Holdings, Inc timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2016
- 🔔Initial public offering as Obalon Therapeutics IncFinal prospectus filed with the SEC on 6 October 2016; shares registered for exchange trading on 27 September 2016.
- 2021
- 💰Record revenue of $14 millionFY2021, the highest of the 7 years on record.
- ✎Renamed ReShape Lifesciences Inc.Formerly Obalon Therapeutics Inc.
- 2025
- ✎Renamed Vyome Holdings, IncFormerly ReShape Lifesciences Inc..
Events of Vyome Holdings, Inc from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.8×
- Free cash flow yield
- -117.6%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -272.9%
- Liabilities / assets
- 42.2%
- Net debt
- $10M
- Revenue growth
- -7.7%
- R&D / revenue
- 3.6%
- Profit per employee
- $-570 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-10M | $-10M | — |
| Dec 2024 | $8M | -7.7% | $-1M | $-1M | -18.1% |
| Dec 2023 | $9M | -22.8% | $-15M | $-11M | -131.2% |
| Dec 2022 | $11M | -17.4% | $-46M | $-46M | -411.1% |
| Dec 2021 | $14M | +20.4% | $-58M | $-63M | -464.3% |
| Dec 2020 | $11M | +244.5% | $-12M | $-22M | -191.4% |
| Dec 2019 | $3M | -64.0% | $-23M | $-24M | -722.0% |
| Dec 2018 | $9M | — | $-37M | $-37M | -410.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-4M | — | — | $-4.86 | — |
| Dec 2024 | $-1M | — | — | $-6001.39 | — |
| Dec 2023 | $-17M | $0M | $-17M | $-110.87 | — |
| Dec 2022 | $-22M | $0M | $-22M | $-108.90 | — |
| Dec 2021 | $-15M | $0M | $-16M | $-288.97 | — |
| Dec 2020 | $-9M | $0M | $-9M | $-5.54 | — |
| Dec 2019 | $-23M | $0M | $-23M | $-5.03 | — |
| Dec 2018 | $-29M | $1M | $-31M | $-19.64 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+100.0% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Aug 28, 20268-KCurrent reportDirectors or officers changed
- Aug 25, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- May 29, 20268-KCurrent reportResults of operations
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 29, 20268-KCurrent reportBylaws amended · Shareholder vote
- Mar 31, 2026DEF 14AProxy statement
- Mar 18, 202610-KAnnual report · period to Dec 2025
- Feb 25, 20268-KCurrent reportMaterial agreement · Other events
- Feb 13, 20268-KCurrent reportRegulation FD disclosure
- Jan 28, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Vyome Holdings, Inc with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-10 M
- Net income
- $-10 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $3 M
- Total equity
- $4 M
As of December-2025
Top 13 institutional investors in Vyome Holdings, Inc#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP | 26,554 | +16,496 (+164.01%) | 0.38% | $0 M | Nov 16, 2026 |
| 2 | Geode Capital Management, LLC | 25,580 | -213 (-0.83%) | 0.36% | $0 M | Nov 6, 2026 |
| 3 | Vanguard Capital Management LLC | 14,927 | +5,464 (+57.74%) | 0.21% | $0 M | Nov 13, 2026 |
| 4 | Focus Partners Wealth | 14,640 | 0 (0.00%) | 0.21% | $0 M | Nov 12, 2026 |
| 5 | HRT Financial LP | 13,834 | -6,484 (-31.91%) | 0.20% | $0 M | Nov 13, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 12,195 | 0 (0.00%) | 0.17% | $0 M | Nov 13, 2026 |
| 7 | Royal Bank Of Canada | 5,856 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 3,091 | -8,817 (-74.04%) | 0.04% | $0 M | Nov 10, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 2,516 | +708 (+39.16%) | 0.04% | $0 M | Nov 16, 2026 |
| 10 | FMR LLC | 1,000 | New | 0.01% | $0 M | Nov 10, 2026 |
| 11 | Caitong International Asset Management Co., Ltd | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 12 | Barclays PLC | 2 | -24 (-92.31%) | 0.00% | $0 M | Nov 6, 2026 |
| 13 | Robinhood Markets, Inc. | 2 | — | 0.00% | $0 M | Nov 18, 2026 |
Mutual funds holding Vyome Holdings, Inc#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 16,294 | $0 M | 0.23% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 9,463 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 3,208 | $0 M | 0.05% | <0.01% | +87% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Vyome Holdings, Inc#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mohanjit JollyDirector | Grant or awardindirect | +454,456 | — | — | 454,456 | Form 4 |
| filed | Venkateswarlu NelabhotlaPresident and CEO, Director | Grant or award | +7 | — | — | 7 | Form 4 |
| filed | Robert Dickey IVChief Financial Officer | Grant or award | +762 | — | — | 762 | Form 4 |
| filed | Thomas StankovichChief Financial Officer | Sell | -48 | $0.250 | $12 | 22,777 | Form 4 |
| filed | Thomas StankovichChief Financial Officer | Sell | -43 | $0.170 | $7 | 22,825 | Form 4 |
| filed | Thomas StankovichChief Financial Officer | Sell | -42 | $0.250 | $11 | 22,868 | Form 4 |
| filed | Thomas StankovichChief Financial Officer | Sell | -39 | $0.230 | $9 | 22,910 | Form 4 |
| filed | Thomas StankovichChief Financial Officer | Sell | -131 | $0.270 | $35 | 22,949 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vyome Holdings, Inc#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 1-for-58.14 reverse split ; 1-for-50 reverse split ; 1-for-3 reverse split ; 1-for-100 reverse split ; 1-for-2.9 reverse split ; 1-for-3 reverse split
Trading halts
- 2026-01-27 15:09 UTC, code LUDP, resumed 15:14 UTC
- 2026-01-27 14:58 UTC, code LUDP, resumed 15:08 UTC
Fails to deliver
- : 2,226 shares at $2.06
- : 2,649 shares at $1.91
- : 1 shares at $1.93
- : 5,920 shares at $1.99
- : 2,338 shares at $2.04
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vyome Holdings, Inc scorecard#
Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 7, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.9×Price to book 3.9× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-117.6%Free cash flow is -117.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.86 vs -6001.39Diluted EPS -4.86 in fiscal 2025 against -6001.39 the year before (report's currency).
- ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$22 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.99 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Vyome Holdings, Inc: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.3−96.0%100% | 8.0−7.7%100% | 8.7−22.8%100% | 11−17.4%100% | 14+20.4%100% | 11r1.6+244%100% | 3.3−63.9%100% | 9.1−8.2%100% | 9.9+192%100% | 3.4—100% | |
| Cost of revenue | 0.1+62.9%31.6% | 0.1r2.9−98.0%0.8% | 3.1−29.5%36.1% | 4.4−15.5%39.5% | 5.3+4.3%38.6% | 5.0r1.0+70.7%44.6% | 3.0−45.6%89.9% | 5.4+12.3%59.6% | 4.8+71.9%48.7% | 2.8—82.8% | |
| Gross profit | 0.2+12.2%68.4% | 0.2r5.1−96.5%2.4% | 5.5−18.4%63.9% | 6.8−18.5%60.5% | 8.3+33.3%61.4% | 6.3r0.6+1792%55.4% | 0.3−91.0%10.1% | 3.7−27.7%40.4% | 5.1+771%51.3% | 0.6—17.2% | |
| Research and development | 0.6+106%184% | 0.3r1.8−87.7%3.6% | 2.3−8.8%26.7% | 2.5+7.1%22.6% | 2.4r2.5−32.3%17.4% | 3.5r2.5−49.3%31.0% | 6.9−35.6%210% | 11+0.5%118% | 11+7.9%107% | 9.9—291% | |
| Selling, general and administrative | 2.4+163%740% | 0.9−88.1%11.2% | 7.5−46.4%87.0% | 14+58.5%125% | 8.9r9.2+89.5%65.4% | 4.7r8.8−71.8%41.5% | 17−44.3%508% | 30+3.9%329% | 29+182%291% | 10—301% | |
| Selling and marketing | — | 3.0−60.4%37.4% | 7.5—87.0% | — | — | — | — | — | — | — | |
| General and administrative | — | 6.9−32.9%86.6% | 10−40.2%119% | 17−29.1%153% | 24r24+131%179% | 11—93.2% | — | — | — | — | |
| Operating expenses | 11+788%3338% | 1.2r13−94.3%15.0% | 21−60.6%241% | 53−19.7%473% | 66r65+254%487% | 19r13−20.6%166% | 24−42.0%718% | 41+3.0%447% | 39+96.5%398% | 20—592% | |
| Operating income | −10—−3269% | −1.0r−7.7—−12.6% | −15—−177% | −46—−412% | −58r−57—−426% | −12r−12—−110% | −23—−708% | −37—−406% | −34—−347% | −20—−575% | |
| Interest expense and finance costs | 0.1−28.8%45.9% | 0.2—2.6% | — | — | — | — | — | — | — | — | |
| Other non-operating income (expense) | −0.0—−7.9% | −0.4r0.2−462%−5.5% | 0.1+1009%1.4% | 0.0—0.1% | — | −0.4—−3.6% | −0.1—−1.9% | −0.2—−2.1% | −0.2—−2.4% | −0.0—−0.6% | |
| Income before tax | — | −7.1—−88.6% | −11—−131% | −47—−415% | −63r−62—−466% | −22—−193% | — | — | — | — | |
| Income tax | — | 0.0−25.0%0.5% | 0.1—0.6% | −0.4—−3.4% | −0.3r−0.1—−2.0% | −0.2r0−1393%−1.6% | 0.0+27.3%0.4% | 0.0+10.0%0.1% | 0.0+400%0.1% | 0.0—0.1% | |
| Net income including minority interests | −10—−3277% | −1.4r−7.1—−18.1% | −11—−131% | −46—−411% | −63r−62—−464% | −22—−191% | — | — | — | — | |
| Minority interests' share of net income | −0.2—−67.5% | — | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −10—−3210% | −1.4r−7.1—−18.1% | −11—−131% | −46—−411% | −63r−62—−464% | −22r−12—−191% | −24—−722% | −37—−411% | −35—−351% | −20—−603% | |
| Earnings per share, basic | -4.86—— | -6,001.39r-13.83—— | -110.87r-1.91—— | -108.90—— | -288.97r-5.00—— | -5.54r-1.59—— | -5.03—— | -19.64r-1.96—— | -2.08—— | -4.85—— | |
| Earnings per share, diluted | -4.86—— | -6,001.39r-13.83—— | -110.87r-1.91—— | -108.90—— | -288.97r-5.00—— | -5.54r-1.59—— | -5.03—— | -19.64r-1.96—— | -2.08—— | -4.85—— | |
| Shares, weighted average (basic) | 2.2+896722%— | 0.0r0.5−99.8%— | 0.1r6.0−75.8%— | 0.4+94.2%— | 0.2r12−94.4%— | 3.9—— | — | — | — | — | |
| Shares, weighted average (diluted) | 2.2+896722%— | 0.0r0.5−99.8%— | 0.1r6.0−75.8%— | 0.4+94.2%— | 0.2r12−94.4%— | 3.9r7.7−17.0%— | 4.7+147%— | 1.9r19−88.6%— | 17+296%— | 4.2—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.0+4789%76.7% | 0.1r0.7−97.7%7.4% | 4.5+15.7%41.8% | 3.9−83.1%34.6% | 23+670%43.3% | 3.0r3.9−79.0%8.0% | 14−33.7%68.9% | 21+0.4%69.7% | 21−71.1%39.8% | 73—92.6% | |
| Short-term investments | — | — | — | — | — | — | 0−100%0.0% | 2.5−89.1%8.4% | 23+832%43.9% | 2.5—3.2% | |
| Receivables | 0.0−85.8%0.0% | 0.0r1.0−99.9%0.2% | 1.7—15.9% | — | — | — | 0.3−67.2%1.4% | 0.9−79.4%2.9% | 4.2—8.0% | 0—0.0% | |
| Inventory | — | 2.5−34.2%178% | 3.7+3.6%35.1% | 3.6+20.2%32.4% | 3.0+33.8%5.7% | 2.2+15.9%6.1% | 1.9+22.5%9.5% | 1.6+11.4%5.2% | 1.4+71.5%2.7% | 0.8—1.0% | |
| Other current assets | 0.1+49.7%1.8% | 0.1r0.3−36.8%5.8% | 0.1+50.0%1.2% | 0.1−55.3%0.8% | 0.2+18.2%0.4% | 0.2r3.9−91.9%0.4% | 2.0−20.4%9.6% | 2.5+43.6%8.1% | 1.7+37.8%3.2% | 1.2—1.6% | |
| Current assets | 5.4+1700%83.7% | 0.3r4.6−97.1%21.9% | 10+3.9%96.6% | 9.9−66.9%89.0% | 30r30+235%57.0% | 8.9r7.8−51.0%24.1% | 18−36.3%89.4% | 29−44.6%94.3% | 52−33.7%97.5% | 78—99.1% | |
| Property, plant and equipment | 0.0−21.6%0.7% | 0.1r0.0−1.4%4.3% | 0.1−91.4%0.6% | 0.7−52.0%6.3% | 1.5+149%2.8% | 0.6r1.0−46.0%1.6% | 1.1−37.8%5.3% | 1.7+29.2%5.7% | 1.3+87.7%2.5% | 0.7—0.9% | |
| Right-of-use (leased) assets | 0.0−50.4%0.5% | 0.1r0.1−76.2%4.3% | 0.3+46.2%2.3% | 0.2−35.7%1.5% | 0.3−42.8%0.5% | 0.5r0.5−56.8%1.3% | 1.1—5.3% | — | — | — | |
| Other intangible assets | 0.30.0%4.8% | 0.3—22.7% | — | 0.3−98.1%2.3% | 14+7.7%26.4% | 13—34.8% | — | — | — | — | |
| Non-current assets | 1.1−1.9%16.3% | 1.1—78.1% | — | — | — | — | — | — | — | — | |
| Total assets | 6.5+370%100% | 1.4r4.8−87.0%100% | 11−4.3%100% | 11−78.8%100% | 53r54+41.7%100% | 37r11+81.7%100% | 20−32.9%100% | 30−42.8%100% | 53−32.6%100% | 79—100% | |
| Accounts payable | 0.6+29.0%10.0% | 0.5r2.2−70.3%36.3% | 1.7−12.3%15.8% | 1.9−44.5%17.3% | 3.5−5.1%6.6% | 3.7r0.6+464%9.9% | 0.6−44.1%3.2% | 1.2−9.2%3.8% | 1.3+114%2.4% | 0.6—0.8% | |
| Debt due within a year | — | 0.8—58.7% | — | — | — | 3.6—9.7% | 0−100%0.0% | 9.9+407%32.7% | 2.0—3.7% | 0—0.0% | |
| Current liabilities | 2.7−52.3%42.1% | 5.7r5.0+52.0%415% | 3.8−49.5%35.4% | 7.5−0.7%67.1% | 7.5r7.3−35.1%14.3% | 12r5.0+192%31.3% | 4.0−76.9%19.5% | 17+72.1%56.7% | 10+118%18.9% | 4.6—5.8% | |
| Long-term debt | — | — | — | — | — | 9.2r0.4—24.7% | 0—0.0% | 0−100%0.0% | 8.0−19.4%15.0% | 9.9—12.5% | |
| Lease liabilities (non-current) | — | 0.0r0.0−78.3%2.4% | 0.2—1.4% | — | — | 0.2r0.4−71.3%0.4% | 0.6—2.8% | — | — | — | |
| Non-current liabilities | — | 0.0—2.4% | — | — | — | — | 0.6+1081%2.8% | 0.0−99.4%0.2% | 8.0−19.3%15.0% | 9.9—12.5% | |
| Total liabilities | 2.7−52.6%42.1% | 5.8r5.0+44.3%418% | 4.0−46.5%37.5% | 7.5−8.7%67.1% | 8.2r8.2−63.7%15.6% | 23r6.0+397%60.9% | 4.5−73.7%22.3% | 17−3.9%56.9% | 18+24.3%33.9% | 14—18.4% | |
| Retained earnings | −88—−1348% | −55r−643—−4012% | −636—−5961% | −624—−5602% | −578r−577—−1100% | −515r−185—−1389% | −172—−846% | −149—−490% | −111—−210% | −77—−97.2% | |
| Shareholders' equity | — | −4.4r−0.3−166%−318% | 6.7+82.0%62.5% | 3.7−91.7%32.9% | 44r46+206%84.4% | 14r4.7−39.9%39.1% | 24r16+83.9%118% | 13−62.7%43.1% | 35−45.4%66.1% | 64—81.6% | |
| Minority interests | 1.3+131995700%20.3% | 0.0—0.0% | — | — | — | — | — | — | — | — | |
| Total equity | 3.8—57.9% | −4.4—−318% | −6.2—−57.9% | — | — | 4.7−70.6%12.6% | 16+20.9%77.7% | 13−62.7%43.1% | 35−45.4%66.1% | 64—81.6% | |
| Total liabilities and equity | 6.5+370%100% | 1.4r4.8−87.0%100% | 11−4.3%100% | 11−78.8%100% | 53r54+41.7%100% | 37r11+81.7%100% | 20−32.9%100% | 30−42.8%100% | 53−32.6%100% | 79—100% | |
| Shares outstanding | 5.9—— | — | 0.4r23−22.1%— | 0.5+45.6%— | 0.4r18−89.8%— | 3.5r7.8−54.9%— | 7.7+228%— | 2.4r24−86.6%— | 18+4.3%— | 17—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0−30.9%3.7% | 0.0—0.2% | — | — | — | 0.3−29.0%3.0% | 0.5—14.6% | — | 0.3+71.9%3.3% | 0.2—5.7% | |
| Share-based compensation | 0.6+214%181% | 0.2−76.0%2.3% | 0.8−63.3%8.8% | 2.1−82.9%18.6% | 12r13+824%89.9% | 1.3r1.1−55.6%11.7% | 3.0−36.4%90.9% | 4.7+44.8%51.6% | 3.2+476%32.7% | 0.6—16.6% | |
| Cash from operating activities | −3.7—−1173% | −0.6r−4.4—−7.7% | −17—−195% | −22—−195% | −15—−113% | −8.6r−10—−75.7% | −23—−697% | −29—−323% | −31—−309% | −19—−571% | |
| Capital expenditure | — | — | −0.0—−0.5% | −0.1—−1.2% | −0.4—−2.6% | −0.2—−1.5% | −0.2—−5.9% | −1.3—−14.1% | −1.0—−10.5% | −0.4—−10.4% | |
| Acquisitions, net of cash acquired | — | — | — | — | −25—−186% | — | — | — | — | — | |
| Cash from investing activities | — | 0.0—0.0% | −0.0—−0.1% | −0.1−105%−0.8% | 1.9—13.6% | −2.4r−0.2−201%−21.2% | 2.4−87.9%71.8% | 20—214% | −22−452%−220% | 6.2—183% | |
| Debt issued | 0.6—188% | — | — | — | — | 0.4−95.7%3.8% | 10—305% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Debt repaid | — | — | — | — | −11—−77.2% | 0—0.0% | −20—−610% | 0—0.0% | — | 0—0.0% | |
| Shares issued | 1.3—401% | — | 13+2003%155% | 0.6—5.7% | — | 0−100%0.0% | 23+138%712% | 9.8—108% | 0—0.0% | — | |
| Cash from financing activities | 8.7+1140%2707% | 0.7r0.7−96.0%8.7% | 18+461%203% | 3.1−90.6%27.8% | 33+201%245% | 11r0.4−17.2%98.0% | 13+33.9%408% | 10.0+1530%110% | 0.6−99.3%6.2% | 83—2440% | |
| Exchange-rate effect on cash | — | — | — | — | 0.0—0.2% | −0.1—−1.0% | — | — | 0—0.0% | 0—0.0% | |
| Change in cash | 4.9+5624%1526% | 0.1r−3.8−85.9%1.1% | 0.6—7.0% | −19−195%−168% | 20+89936%146% | 0.0r−10—0.2% | −7.1−9128%−217% | 0.1—0.9% | −52−175%−523% | 70—2052% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.2−93.8%100% | 0.1+67.5%100% | 0.0−97.8%100% | 0.0−97.2%100% | 0.0*−40.5%100% | 0.0−98.5%100% | 1.2−36.8%100% | 1.1−42.7%100% | 0.1*−96.9%100% | 2.3—100% | 2.0—100% | 1.9—100% | 2.0*—100% | |
| Cost of revenue | 0.1—49.6% | 0.0+88.2%53.8% | 0.0−40.5%56.8% | 0.0−66.2%47.3% | 0.0*—39.6% | 0.0−65.1%47.9% | 0.0r0.6−96.9%2.1% | 0.0r0.4−94.3%4.0% | — | 0.0r0.9—2.1% | 0.8—42.3% | 0.8—40.1% | 0.1*—7.1% | |
| Gross profit | 0.1−70.3%50.4% | 0.0+48.5%46.2% | 0.0−51.9%43.2% | 0.0−89.2%52.7% | 0.0*−64.8%60.4% | 0.0−51.3%52.1% | 0.0r0.6−97.9%2.0% | 0.2r0.7−86.7%13.9% | 0.1r1.3*−96.6%102% | 0.0r1.4—1.6% | 1.1—57.7% | 1.2—59.9% | 1.8*—92.9% | |
| Research and development | 2.0+607%1281% | 0.4+933%707% | 0.5+533%1880% | 0.7+638%2109% | 0.4*+460%1035% | 0.0−40.6%115% | 0.1r0.5−79.9%6.4% | 0.1r0.4−81.3%8.1% | 0.1r0.5*−90.9%110% | 0.1r0.4—2.9% | 0.4—20.3% | 0.5—24.9% | 0.7*—37.3% | |
| Selling, general and administrative | 2.5+53.0%1616% | 0.6−24.7%1096% | 0.4+37.5%1354% | 0.5+83.9%1512% | 1.0*+303%2726% | 0.8+242%2438% | 0.3−60.4%21.4% | 0.3−74.5%23.3% | 0.2*−82.3%403% | 0.2r0.7—10.8% | 0.7—34.1% | 1.0—52.4% | 1.4*—70.5% | |
| Selling and marketing | — | — | — | — | — | — | 0.6−13.0%46.9% | 0.5−48.1%47.5% | — | — | 0.7—34.1% | 1.0—52.4% | — | |
| General and administrative | — | — | — | — | — | — | 1.6−16.5%128% | 1.6−13.1%146% | 0.9*−46.4%1395% | 2.1—90.8% | 1.9r2.1—97.0% | 1.9—96.3% | 1.6*—80.7% | |
| Operating expenses | 4.4−53.8%2904% | 1.0−87.8%1807% | 0.9+151%3243% | 1.1+224%3629% | 1.4*+332%3768% | 8.6+2601%24814% | 0.3r3.4−89.1%28.1% | 0.4r2.9−89.5%31.8% | 0.3r3.0*−91.5%519% | 0.3r3.2—13.9% | 3.2—162% | 3.4—174% | 3.7*—189% | |
| Operating income | −4.4—−2854% | −1.0—−1761% | −0.9—−3200% | −1.1—−3577% | −1.4*—−3707% | −8.6—−24762% | −0.3r−2.8—−26.1% | −0.2r−2.2—−17.9% | −0.3r−1.7*—−417% | −0.3r−1.8—−12.3% | −2.1—−105% | −2.2—−114% | −1.9*—−95.6% | |
| Interest expense and finance costs | 0.0−89.9%12.4% | 0.0−88.5%5.1% | 0.0−94.1%12.3% | 0.0−94.8%9.0% | 0.0*−81.2%27.2% | 0.0−44.0%73.9% | 0.1—4.5% | 0.1—4.9% | 0.1*—85.9% | 0.0—2.0% | — | — | — | |
| Other non-operating income (expense) | 0.5—296% | 0.1—157% | 0.1+826%530% | 0.1—457% | 0.1*—206% | −0.0—−60.6% | 0.0r0.1−73.8%1.2% | −0.1r0.1−480%−8.5% | −0.1*−144%−82.3% | −0.3r0.1—−11.6% | 0.1—3.0% | 0.0—1.3% | 0.1*—5.8% | |
| Income before tax | — | — | — | — | — | — | −2.6—−211% | 1.5—133% | −1.8*—−2859% | −1.6—−68.7% | −1.6—−80.4% | −2.2—−112% | −1.7*—−84.1% | |
| Income tax | — | — | — | — | — | — | 0.0−46.7%0.6% | 0.0−50.0%0.6% | 0.0*−83.9%8.1% | 0.0—0.3% | 0.0—0.8% | 0.0—0.7% | 0.0*—1.6% | |
| Net income including minority interests | −3.9—−2557% | −0.9—−1604% | −0.7—−2670% | −1.0—−3120% | −1.3*—−3501% | −8.6—−24823% | −0.3—−24.9% | −0.3r1.5—−26.4% | −0.3r−1.8*—−499% | −0.5—−23.9% | −0.5—−23.7% | −0.1r−2.2—−6.5% | −1.7*—−85.7% | |
| Minority interests' share of net income | −0.2—−102% | −0.0—−77.4% | −0.0—−127% | −0.0—−71.6% | −0.1*—−148% | −0.2—−466% | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −3.8—−2456% | −0.9—−1527% | −0.7—−2543% | −1.0—−3048% | −1.2*—−3353% | −8.4—−24356% | −0.3r−2.6—−24.9% | −0.3r1.5—−26.4% | −0.3r−1.8*—−499% | −0.5r−1.6—−23.9% | −1.6—−81.2% | −2.2—−113% | −1.7*—−85.7% | |
| Earnings per share, basic | — | -0.13—— | -0.10—— | -0.15—— | — | -3.06r-3.12—— | -799.90r-2.25—— | -761.59r18.98—— | — | -1,419.10r-3.11—— | -91.56r-0.06—— | -135.37r-0.09—— | — | |
| Earnings per share, diluted | — | -0.13—— | -0.10—— | -0.15—— | — | -3.06r-3.12—— | -799.90r-2.25—— | -761.59r18.98—— | — | -1,419.10r-3.11—— | -91.56r-0.06—— | -135.37r-0.09—— | — | |
| Shares, weighted average (basic) | 7.0+154%— | 7.0+154%— | 7.0+1818172%— | 6.7+1733131%— | — | 2.8+714535%— | 0.0r1.2−97.8%— | 0.0r0.1−97.6%— | — | 0.0r0.5—— | 0.0r25—— | 0.0r23—— | — | |
| Shares, weighted average (diluted) | — | — | — | 6.7+1733131%— | — | 2.8+714535%— | 1.2+6609%— | 0.0r0.1−97.6%— | — | 0.0r0.5—— | 0.0r25—— | 0.0r23—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 7.0—80.8% | 7.0+21.9%80.8% | 7.9+91.3%86.0% | 8.8+250%86.4% | 5.0+4789%76.7% | 5.7+668%81.0% | 4.1+34258%45.7% | 2.5+5.7%174% | 0.1r0.7−97.7%7.4% | 0.7—58.1% | 0.0r1.1—0.2% | 2.4—28.9% | 4.5—41.8% | |
| Receivables | 0.0—0.1% | 0.0−60.5%0.1% | 0.0−99.8%0.0% | 0.0−100.0%0.0% | 0.0−85.8%0.0% | 0.0−98.2%0.3% | 1.40.0%15.5% | 0.7−56.3%48.5% | 0.0r1.0−99.9%0.2% | 1.3—102% | 1.4—21.9% | 1.6—19.4% | 1.7—15.9% | |
| Inventory | — | — | — | — | — | — | 2.6−21.4%28.3% | 2.5−27.0%175% | 2.5−34.2%178% | 2.9—230% | 3.2—50.8% | 3.5—42.1% | 3.7—35.1% | |
| Other current assets | 0.2—2.3% | 0.2+115%2.3% | 0.2+26.9%1.9% | 0.2−44.1%1.6% | 0.1+49.7%1.8% | 0.1+81.2%1.3% | 0.1+145%1.5% | 0.3+306%19.7% | 0.1r0.3−36.8%5.8% | 0.1—4.0% | 0.1—0.9% | 0.1—0.9% | 0.1—1.2% | |
| Current assets | 7.6—88.2% | 7.6+25.9%88.2% | 8.2−8.0%88.9% | 9.2+45.6%90.0% | 5.4+1700%83.7% | 6.0+13.1%85.7% | 8.9+45.6%98.2% | 6.3−20.3%436% | 0.3r4.6−97.1%21.9% | 5.3—418% | 6.1—95.2% | 7.9—95.9% | 10—96.6% | |
| Property, plant and equipment | 0.0—0.5% | 0.0−17.8%0.5% | 0.0+41.4%0.5% | 0.0+30.7%0.4% | 0.0−21.6%0.7% | 0.1+16.7%0.7% | 0.0−37.5%0.3% | 0.0−37.0%2.4% | 0.1r0.0−1.4%4.3% | 0.0—3.4% | 0.0—0.8% | 0.1—0.7% | 0.1—0.6% | |
| Right-of-use (leased) assets | 0.0—0.1% | 0.0−80.0%0.1% | 0.0−81.3%0.2% | 0.0−78.5%0.2% | 0.0−50.4%0.5% | 0.0−79.2%0.5% | 0.1−60.9%0.9% | 0.1−56.2%6.9% | 0.1r0.1−76.2%4.3% | 0.2—13.8% | 0.2—3.2% | 0.2—2.7% | 0.3—2.3% | |
| Other intangible assets | 0.3—3.6% | 0.30.0%3.6% | 0.3—3.4% | 0.3—3.1% | 0.30.0%4.8% | 0.3—4.5% | — | — | 0.3—22.7% | — | — | — | — | |
| Non-current assets | 1.0—11.8% | 1.0+0.5%11.8% | 1.0—11.1% | 1.0—10.0% | 1.1−1.9%16.3% | 1.0—14.3% | — | — | 1.1—78.1% | — | — | — | — | |
| Total assets | 8.6—100% | 8.6+22.2%100% | 9.2+1.6%100% | 10+606%100% | 6.5+370%100% | 7.0+451%100% | 9.0+41.2%100% | 1.4r6.5−82.5%100% | 1.4r4.8−87.0%100% | 1.3r5.6—100% | 6.4—100% | 8.2—100% | 11—100% | |
| Accounts payable | 0.4—5.1% | 0.4−73.6%5.1% | 0.5−59.4%6.0% | 0.5−68.4%5.2% | 0.6+29.0%10.0% | 1.7−21.4%23.5% | 1.3+30.7%14.9% | 1.7+28.3%117% | 0.5r2.2−70.3%36.3% | 2.1—165% | 1.0—16.1% | 1.3—16.0% | 1.7—15.8% | |
| Debt due within a year | — | — | — | — | — | — | — | — | 0.8—58.7% | — | — | — | — | |
| Current liabilities | 2.1—24.0% | 2.1−33.8%24.0% | 1.9−41.7%20.3% | 2.1−48.0%21.1% | 2.7−52.3%42.1% | 3.1−22.5%44.3% | 3.2−0.1%35.4% | 4.1+17.2%286% | 5.7r5.0+52.0%415% | 4.0—315% | 3.2—50.1% | 3.5—42.8% | 3.8—35.4% | |
| Lease liabilities (non-current) | — | — | — | — | — | 0.0−89.4%0.1% | — | 0.0−89.0%1.0% | 0.0r0.0−78.3%2.4% | 0.1—6.0% | 0.1—1.6% | 0.1—1.5% | 0.2—1.4% | |
| Non-current liabilities | — | — | — | — | — | 0.0—0.1% | — | — | 0.0—2.4% | — | — | — | — | |
| Total liabilities | 2.1—24.0% | 2.1−33.9%24.0% | 1.9−41.7%20.3% | 2.1−59.2%21.1% | 2.7−52.6%42.1% | 3.1−24.3%44.4% | 3.2−4.7%35.4% | 5.3+42.1%364% | 5.8r5.0+44.3%418% | 4.1—323% | 3.4—52.5% | 3.7—44.9% | 4.0—37.5% | |
| Retained earnings | −90—−1046% | −90—−1046% | −89—−972% | −89—−869% | −88—−1348% | −86—−1225% | −644—−7132% | −641—−44435% | −55r−643—−4012% | −641—−50140% | −639—−10001% | −638—−7748% | −636—−5961% | |
| Shareholders' equity | — | — | — | — | — | 2.5+70.1%35.9% | 5.8+92.1%64.6% | 1.2−72.9%85.2% | −4.4r−0.3−166%−318% | 1.5—116% | 3.0—47.5% | 4.5—55.1% | 6.7—62.5% | |
| Minority interests | 1.2—14.1% | 1.2−12.3%14.1% | 1.3—13.8% | 1.3—12.7% | 1.3+131995700%20.3% | 1.4—19.7% | — | — | 0.0—0.0% | — | — | — | — | |
| Total equity | 6.5—76.0% | 6.5+67.1%76.0% | 7.3—79.7% | 8.0—78.9% | 3.8—57.9% | 3.9—55.6% | −5.0r−5.0—−55.3% | −4.7r−4.7—−325% | −4.4—−318% | −4.1—−320% | −4.0—−62.1% | −6.3—−76.6% | −6.2—−57.9% | |
| Total liabilities and equity | 8.6—100% | 8.6+22.2%100% | 9.2+1.6%100% | 10+57.1%100% | 6.5+370%100% | 7.0+25.5%100% | 9.0+41.2%100% | 6.5−21.2%449% | 1.4r4.8−87.0%100% | 5.6—439% | 6.4—100% | 8.2—100% | 11—100% | |
| Shares outstanding | 7.0—— | 7.0—— | 7.0+167%— | 7.0+5174%— | 5.9—— | — | 2.6−91.1%— | 0.1−99.4%— | — | 0.7—— | 29—— | 23—— | 0.4r23—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0−19.4%6.9% | 0.0−3.7%4.7% | 0.0−12.1%9.7% | 0.0−26.1%8.2% | 0.0*−30.4%7.4% | 0.0−36.6%8.1% | 0.0—0.2% | 0.0—0.3% | 0.0*—6.3% | 0.0—0.2% | — | — | — | |
| Share-based compensation | 0.2−68.3%128% | 0.2*−69.4%303% | 0.0*−7.9%41.0% | 0.0−62.0%18.0% | 0.0*−79.9%8.3% | 0.6+1694%1658% | 0.0−81.5%1.0% | 0.0−79.2%1.3% | 0.0*−86.4%24.4% | 0.0—1.4% | 0.1—3.3% | 0.1—3.7% | 0.1*—5.5% | |
| Cash from operating activities | −4.5—−2931% | −0.6*—−1082% | −0.9*—−3353% | −1.4—−4545% | −1.5r−1.5*—−4158% | −1.7r4.3*−161%−4965% | −0.3r−4.5*—−24.7% | −0.2r−2.1—−18.3% | −0.0r−0.7*—−4.8% | 2.8r−0.3*—123% | −1.4*—−69.1% | −2.1—−107% | −2.5*—−124% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | — | — | — | — | — | — | — | — | 0.0*—2.4% | — | — | — | 0*—0.0% | |
| Debt issued | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | — | — | — | |
| Shares issued | 5.9—3847% | 0*—0.0% | −0.0*−100%−11.1% | 5.3+11.2%16742% | 0.6*—1650% | −10*—−29397% | 6.1*—491% | 4.8−53.4%427% | — | — | 0*—0.0% | 10—525% | 1.0*—49.8% | |
| Cash from financing activities | 5.8−26.6%3790% | −0.3*−104%−498% | −0.0*−100%−11.1% | 5.3+3206%16742% | 0.8r0.8*+1407%2204% | 7.1r−2.2*+1038%20383% | 0.6r6.1*—50.8% | 0.2r3.9—14.4% | 0.1r0.7*−99.0%87.0% | 0.6r0*—27.1% | — | — | 5.5*—276% | |
| Change in cash | 1.2−77.9%816% | −0.9*−117%−1605% | −0.9*−379%−3370% | 3.8—12071% | −0.7*−1467%−1983% | 5.3r2.2*+54.8%15374% | 0.3r1.6*—26.2% | −0.0r1.8—−3.9% | 0.1r−0.1*−98.2%86.3% | 3.4r−0.3*—150% | −1.3*—−67.5% | −2.1—−107% | 3.0*—152% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Vyome Holdings, Inc sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Sale of products(total)$0 M55%+31%
- Licensing and milestone fees – Luliconazole$0 M37%—
- Royalty income related to above product sales$0 M8.8%-40%
Business segments
- Pharmaceutical$0 M100%+23%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Vyome Holdings, Inc#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 8 · Unregistered share sale 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 5 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Auditor changedMaterial agreement | 8-K | |
| Acquisition or sale completedDirectors and officersUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 28, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2018 | $10 M | Private placement after listing | $10 to $50 million | 21 | equity | SEC |
| Aug 2014 | $16 M | No. 4 | $10 to $50 million | 5 | equity | SEC |
| Dec 2012 | $5 M | No. 3 | $2 to $10 million | 1 | equity | SEC |
| May 2012 | $17 M | No. 2 | $10 to $50 million | 3 | equity | SEC |
| Feb 2012 | $2 M | No. 1 | Under $2 million | 2 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | 49 | · | · | · | · | · | · | · | · | 49 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 49 people (50% of workforce) | Restructuring planSEC 8-K | “On April 2, 2019, the Company notified approximately 49 employees whose employment will be terminated, or approximately 50% of its workforce, with the intent to refocus activities,…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Vyome Holdings, Inc compares in Biotechnology
- Market cap$14 M · higher than 14% of 726
- Revenue growth-7.7% · higher than 35% of 438
- Price / book3.9× · lower than 40% of 534
- FCF yield-117.6% · higher than 9% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vyome Holdings, Inc🇺🇸 | $14 M | — | — | -7.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 7, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vyome Holdings, Inc? Verify and update this profile — free
Show Vyome Holdings, Inc's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.